(An open ended equity scheme investing in Pharma and Healthcare sector)
(An open ended equity scheme investing in Pharma and Healthcare sector)
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
NAV Details (As on July 31, 2025)| Regular IDCW | : ₹ 10.0988 |
| Regular Growth | : ₹ 10.0988 |
| Direct IDCW | : ₹ 10.1167 |
| Direct Growth | : ₹10.1167 |
Benchmark Index (Tier 1)BSE Healthcare TRI
Date of AllotmentJune 27, 2025
Fund Manager | Fund Manager | Managing fund since | Experience |
| Mr. Sanjay Chawla | 27-Jun-25 | 33 years |
Load Structure
Exit Load: • Redemption/ switch out of units upto 10% of the
units allotted before 1 year from date of allotment- Exit
load -NIL. • For redemption/switch out of units above 10%
of units allotted within 1 year from the date of allotment-
1.00% of applicable NAV. • For redemption/switch out of
units after 1 year from the date of allotment-Nil.
For detailed load structure please refer Scheme
Information Document.
Minimum Application Amount:
₹ 1,000 and in multiples of ₹ 1
thereafter.
Minimum Additional Purchase Amount:₹ 1,000 and in
multiples of ₹ 1 thereafter.
| Monthly AAUM## As on July 31, 2025 | : ₹ 661.89 Crores |
| AUM## As on July 31, 2025 | : ₹ 670.42 Crores |
## including inter-scheme Investments, if any, by other schemes of Baroda BNP Paribas Mutual Fund, as may be applicable
| NAME OF INSTRUMENT | % of Net Assets | |
| Pharmaceuticals & Biotechnology | 66.09% | |
| ✔ Sun Pharmaceutical Industries Limited | 12.09% | |
| ✔ Divi's Laboratories Limited | 5.90% | |
| ✔ Mankind Pharma Limited | 5.51% | |
| ✔ Cipla Limited | 5.16% | |
| ✔ Gland Pharma Limited | 3.60% | |
| ✔ Abbott India Limited | 3.59% | |
| Torrent Pharmaceuticals Limited | 3.27% | |
| Ajanta Pharma Limited | 3.05% | |
| Biocon Limited | 2.98% | |
| Cohance Lifesciences Limited | 2.98% | |
| IPCA Laboratories Limited | 2.85% | |
| AstraZeneca Pharma India Limited | 2.74% | |
| JB Chemicals & Pharmaceuticals Limited | 2.64% | |
| Aurobindo Pharma Limited | 2.55% | |
| Laurus Labs Limited | 2.48% | |
| Concord Biotech Limited | 2.21% | |
| Dr. Reddy's Laboratories Limited | 1.42% | |
| Natco Pharma Limited | 1.07% | |
| Healthcare Services | 21.39% | |
| ✔ Apollo Hospitals Enterprise Limited | 5.59% | |
| ✔ Max Healthcare Institute Limited | 4.78% | |
| ✔ Fortis Healthcare Limited | 4.03% | |
| ✔ Aster DM Healthcare Limited | 3.43% | |
| Rainbow Childrens Medicare Limited | 2.31% | |
| Dr. Lal Path Labs Limited | 1.25% | |
| Insurance | 2.66% | |
| ICICI Prudential Life Insurance Company Limited | 2.66% | |
| Healthcare Equipment & Supplies | 2.17% | |
| Poly Medicure Limited | 2.17% | |
| LESS THAN 0.75% EXPOSURE | 0.98% | |
| TOTAL EQUITY HOLDING | 93.29% | |
| Total Fixed Income Holdings | ||
| TREPS, Cash & Other Net Current Assets | 6.71% | |
| GRAND TOTAL | 100.00% |
Investment in Top 10 scrips constitutes 53.68% of the portfolio
The scheme currently does not have Distribution History.
| TER - Regular Plan (%) | 2.28% |
| TER - Direct Plan (%) | 0.43% |
| Portfolio Turnover Ratio | 0.00 |
* The information contained in this report has been obtained from sources considered to be authentic and reliable. This quantitative data does not purport to be an offer for purchase and sale of mutual fund units.
| No of Stocks | 28 |
| Portfolio RoE (%) | 15.29 |
| EPS Growth (%) | 27.71 |
➤ Long term capital appreciation.
➤ Investing predominantly in equity and equity related instruments of Pharma and Healthcare companies
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (BSE Healthcare TRI): basis it’s constituents; as on July 31, 2025
For complete portfolio, kindly refer the website https://www.barodabnpparibasmf.in/
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.